CCRM has a history of investment in scalable, end-to-end manufacturing platforms, strong technology partnerships, and a demonstrated commitment to staying at the leading edge of the field.

We have made significant investments in the following enabling technologies:

  • Scale-out/up infrastructure for upstream and downstream process development (PD)
  • System automation and closure
  • Analytics discovery and development
  • Equipment to support Good Manufacturing Practices (GMP)-compliant manufacturing
  • Equipment to support in-house quality control

These technologies are critical for GMP-compliant PD and process characterization that moves beyond pre-clinical and early-phase production towards fit-for-purpose commercial manufacturing of therapeutic products.

CCRM leverages technology partnerships to develop flexible and customized solutions. In addition to our major collaboration with Cytiva, we strive to build a variety of partnerships that support a technology-agnostic approach to PD and manufacturing.

 

Learn more about the other pillars in our approach

Customer Testimonials

We’ve found an ongoing partner [in CCRM] – Dr. Ralph Brandenberger, SVP Technical Operations, Nkarta

[The team] really helped us get to where we are today. – Dr. Lara Ionescu Silverman, PhD, Senior Director, Research and Development, DiscGenics

It almost felt like they [CCRM] were an extension of our team. The culture and adaptive nature, flexibility and communication were excellent. – Edel O’Toole, Senior Director Project & Vendor Management, Avectas

Read more about the CCRM and OmniaBio team’s expertise in OmniaBio’s latest blog posts.